A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

A Multi-center, Randomized, Double-masked, Placebo-controlled, Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity

LIPO-102 is under evaluation for treatment of abdominal adiposity

Inclusion Criteria:

• 18 - 50 years old inclusive
• Localized area of abdominal subcutaneous adiposity of Grade 3 or above on the P-PNS or C-PNS
• BMI < 25kg/m sq
• Stable diet and exercise and body weight

Exclusion Criteria:

• Prior treatment of abdominal subcutaneous adipose tissue
• Females within 12 months postpardum
• Known hypersensitivity to the drugs or components